Highlight
- IL-10-neutralising autoantibodies were identified in approximately 2% of pediatric-onset IBD patients without known monogenic causes.
- These autoantibodies persist longitudinally under standard immunosuppressive therapies but disappear following hematopoietic stem-cell transplantation (HSCT).
- Presence of IL-10 neutralising autoantibodies may represent a unique immunological subtype with distinct clinical features and treatment considerations in pediatric IBD.
- Screening for IL-10 autoantibodies via functional assays could guide personalized management strategies in this patient population.
Study Background
Inflammatory bowel disease (IBD) encompassing Crohn’s disease and ulcerative colitis manifests as chronic intestinal inflammation with heterogeneous pathogenesis. While genetic variants, particularly monogenic causes, are recognized drivers in early-onset cases, some pediatric patients lack identifiable genetic abnormalities, complicating diagnosis and management. Interleukin-10 (IL-10) is a key anti-inflammatory cytokine critical to maintaining intestinal immune homeostasis; disruptions in IL-10 pathways have been linked to severe IBD phenotypes. Recently, autoantibodies neutralising IL-10 have emerged as a potential novel mechanism fueling intestinal inflammation in IBD, but their prevalence, longevity, and clinical consequences in children remain poorly defined. Addressing this void is essential, as identifying such autoantibodies could refine IBD classification and inform tailored therapeutic approaches.
Study Design
This cross-sectional analysis evaluated plasma samples from 318 pediatric patients diagnosed with intestinal inflammatory and autoimmune conditions at a specialized tertiary center. The cohort included 239 children with IBD, 37 with autoimmune enteropathy, and 42 with congenital diarrhoeal disorders. IL-10-neutralising autoantibodies were detected using cell-based functional assays measuring the inhibition of IL-10 activity under stimulated conditions, thereby assessing biological relevance rather than solely antibody presence. Longitudinal plasma samples were available for a subset, enabling evaluation of autoantibody persistence over time. The study also incorporated genetic testing to exclude known monogenic IBD variants, facilitating subgroup analyses. Clinical data were reviewed to assess correlations between autoantibody status and disease features or therapeutic interventions, including immunosuppression, hematopoietic stem-cell transplantation (HSCT), and surgical procedures.
Key Findings
Among 239 pediatric IBD patients, five individuals (2.1%, 95% CI 0.7%–4.8%) had plasma autoantibodies that functionally neutralised 2.5 ng/mL of IL-10, with three maintaining neutralisation at higher IL-10 concentrations (5 ng/mL). Notably, all these patients lacked known monogenic IBD-causing genetic variants. In the subgroup without genetic monogenic variants (n=192), the frequency was slightly higher at 2.6%. Autoantibodies were exclusive to IBD patients and absent in those with autoimmune enteropathy or congenital diarrhoeal disorders, underscoring specificity.
Longitudinal data from three patients confirmed persistence of IL-10-neutralising autoantibodies for 3 and 9 years post-baseline in two cases, despite ongoing immunosuppressive treatment. The third patient’s autoantibodies became undetectable after HSCT, suggesting therapeutic eradication of the autoantibody-producing clone. Additional clinical observations implied declines in autoantibody titres possibly related to colectomy or ileostomy in some patients, although data were limited.
Clinically, the patients displayed heterogeneous disease presentations without clear patterns in phenotype or severity. This heterogeneity suggests IL-10 autoantibody positivity alone does not define a uniform clinical syndrome but may mark a subset with unique immunopathological pathways.
Expert Commentary
This pioneering study provides robust evidence that IL-10-neutralising autoantibodies contribute to the immunopathology of a minority of pediatric IBD cases without known monogenic mutations. The use of functional assays rather than simple antibody detection strengthens the biological relevance of these findings. Persistence of these autoantibodies despite standard immunosuppression highlights their resistance to conventional therapies, whereas their clearance after HSCT emphasizes potential curative approaches targeting the immune source.
The clinical heterogeneity observed implies that IL-10 autoantibody positivity is likely part of a complex, multifactorial disease process, rather than a single monogenic entity. However, identifying these autoantibodies may help stratify patients for alternative therapeutic modalities, such as HSCT or novel biologics targeting IL-10 pathways. Verification in larger cohorts and integration with other biomarkers will be necessary to delineate precise clinical phenotypes and treatment responses.
Limitations include the relatively small number of autoantibody-positive patients, restricted longitudinal follow-up, and potential selection bias inherent in tertiary referral populations. Future studies should validate findings in broader community cohorts and explore mechanistic insights into autoantibody production and immunological consequences.
Conclusion
IL-10-neutralising autoantibodies are a rare but persistent immunologic feature in pediatric-onset IBD without monogenic causes. Their presence delineates a subgroup characterized by resistance to standard immunosuppression and possibility of eradication via HSCT. Functional screening for these autoantibodies should be considered in challenging pediatric IBD cases for precision diagnosis and to tailor therapeutic strategies. Continued research is warranted to expand understanding of the disease mechanisms, improve patient stratification, and develop targeted treatments addressing IL-10 pathway disruptions.
Funding and Clinical Trial Registration
Details of funding sources were not provided in the abstract. No clinical trial registration information was specified.
References
1. Yalcinkaya A, Sandström E, Degrace EJ, et al. IL-10-neutralising autoantibodies in paediatric-onset inflammatory bowel disease. Gut. 2026 Jul 8. PMID: 42419823.
2. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361(21):2033-2045.
3. Caruso R, Warner N, Inohara N, Núñez G. NOD1 and NOD2: signaling, host defense, and inflammatory disease. Immunity. 2014;41(6):898-908.
(lang: en, multilang: vi,ja,zh)
